SHANGHAI MICURX PHARMACEUTICAL CO., LTD.

AicurisPharmaGermany

70% match

AiCuris Anti-infective Cures AG is a biopharmaceutical company headquartered in Wuppertal, Germany. The company specializes in the research and development of innovative, life-saving anti-infective therapies designed to address critical needs in immunocompromised patients.

QureTech BioBiotechnology, Drug DiscoverySweden

68% match

QureTech Bio is a biotechnology company that develops treatments to defeat bacterial virulence and restore antibiotic susceptibility, specifically targeting drug-resistant infections such as Staphylococcus aureus. The company serves the pharmaceutical and healthcare sectors by advancing novel antibacterial portfolios and seeking partnership opportunities.

Protez PharmaceuticalsPharmaceuticalsUnited States

67% match

Protez Pharmaceuticals is a pharmaceutical and medical research company founded in 2003 and focused on the discovery and development of novel injectable and oral small molecule antibiotics for hospital-based, difficult-to-treat infections. The company was acquired by Novartis AG in June 2008.

TenNor Therapeutics (Suzhou) Limited specializes in researching, developing, and bringing to market unique therapies for illnesses arising from bacterial infections and bacterial metabolic functions. Its robust product pipeline includes Rifasutenizole (TNP-2198), designed to combat Helicobacter pylori infections. Another key asset, Rifaquizinone (TNP-2092), is being advanced in an injectable formulation to treat Periprosthetic Joint Infection (PJI), Acute Bacterial Skin and Skin Structure Infections (ABSSSI), and infections associated with Left Ventricular Assist Devices (LVADs). An oral variant of TNP-2092 is aimed at addressing conditions linked to gut bacterial metabolism, such as Hepatic Encephalopathy (HE) and Irritable Bowel Syndrome with Diarrhea (IBS-D). Furthermore, their development programs feature a topical TNP-2092 for confronting drug-resistant bacterial strains and biofilm-mediated infections; TNBi-1, a novel narrow-spectrum small molecule for H. pylori; TNBi-2, a broad-spectrum, multi-targeting small molecule for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD); and TNBm-1, a broad-spectrum bifunctional small molecule for metabolic disorders. The company was established in 2012 and maintains its headquarters in Suzhou, China.

Paratek PharmaceuticalsPharmaceuticalsUnited States

66% match

Paratek Pharmaceuticals is a biopharmaceutical company that develops and commercializes therapies for complex medical conditions, focusing on infectious diseases and antimicrobial resistance. The company's product portfolio includes NUZYRA, an antibiotic for bacterial infections, and XHANCE, a nasal spray for chronic rhinosinusitis. These treatments are designed to serve adult patients with significant unmet medical needs.

CureGene PharmaceuticalPharmaceuticalsChina

65% match

Shanghai CureGene Pharmaceutical Co., Ltd. is a biopharmaceutical company founded in Zhangjiang, Shanghai, in 2018. It specializes in developing state-of-the-art medications and has built a globally leading targeted prodrug platform.